commerci disrupt expect result
guidanc confirm market materi wors
thesi base omnia clinic readout manag
commerci turnaround call
encourag market outlook present overhang
pt
miss revenu provid guidanc estim
announc revenu vs mse includ us revenu
vs mse ex-u revenu vs mse miss
driven compani decis exit certain high volum product order
adjust inventori dynam us revenu would closer
number line estim quarter
would maintain flat us share y/i adjust
notwithstand liber interpret impli revenu prior period
overst clear impact market
pressur peer addit well document commerci disrupt nevro
yet provid guidanc guidanc came
sharpli estim consensu expect
preview guidanc revis magnitud reduct market
slowdown sever discuss dynam detail
materi chang market dynam impact near-term
outlook fundament thesi surround continu see
materi opportun omnia pdn nsbp better commerci
execut new manag earli assess encourag
commentari reinforc confid commerci turnaround later
year previous cautiou commerci execut see
downgrad last year upgrad share recent given view new
platform launch omnia expans underappreci
new ceo keith grossman could address commerci concern
new product launch began impact mr grossman commentari
commerci state busi evidenc understand key
issu short period time commerci dysfunct seriou
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
initi expect broader improv could seen
consist thesi near-term commentari around improv trial
trend concur april dilig admittedli earli assess
slope recoveri curv
market growth meaning disconnect materi chang
emerg quarter rel thesi market expect
market contract upper teen growth upper singl digit near
term varieti reason discuss recent note see market
growth mean includ lack new product launch
anniversari high growth rate major major player
report market model suggest us market flat slightli
declin quarter repres pt momentum deceler
uncov defin factor explain chang isol
interim much wors expect one quarter
make trend reduc market model estim model
us market growth year discuss whether market
return top end histor rang next year key question
could aid easier comp platform launch
interim note item focu
adjust inventori dynam q/q declin would
instead report line abbott
declin boston declin confirm weak
quarter market share
abbott boston reiter expect doubl digit
market growth admittedli prescient predict
note improv trial trend
channel check indic recoveri april weak
unclear reflect broader devic dynam us
devic market soft see devic growth
confid market return high end histor
trend stem belief undertr popul opioid
crisi greater innov higher level clinic evid
elev vs prior
materi risk remain focus possibl reimburs
pressur outsid california worker comp seen
extrapol guid year guidanc impli sequenti growth
midpoint vs manag
commentari encourag trial trend seem
reflect guidanc sens primari disconnect reflect continu
inventori trend describ prudent conservat
q/q increas line histor trend would impli revenu
view guidanc quarter risk-adjust help channel
check mention manag commentari suggest
inventori issu sequenti affect y/i challeng
comp assum revenu tick sequenti throughout year
largest uplift result season new platform launch
salesforc initi assum risk-adjust baselin year
appli histor season trend revenu along
sequenti improv back half lead us move
revenu estim reflect declin us revenu
exclud inventori dynam could base
trend reflect closer declin underli basi
move market model made adjust market model
pend result later month updat us
market growth assumpt year mid-singl digit growth
boston low-singl digit growth abbott declin
compani work transit model
market grow model us franchis grow net
easier comp inventori headwind reflect growth rate
line prior growth estim lower revenu base driven
convict new platform launch admittedli estim
appear elev current trend upsid market nervo share
next two quarter meaning implic outlook
path valu creation expect quarter
clear event expect transit year given weaker
devic growth across sector peer result expect pressur
result magnitud guidanc reduct market
deceler quarter unnerv investor evid market
busi stabil next import catalyst
could serv stabil event point
near intermedi term market growth speed
effect commerci initi improv growth
recept new platform launch key proof point
stock along clinic outcom senza-pdn potenti senza-
nsrbp
area think mr grossman add addit valu includ
stabil improv commerci infrastructur address
imbal us ex-u perform geograph mix
ad product adjac seen peer rf ablat
drg recent boston vertiflex acquisit see vertiflex
price target move lower revenu
estim cycl model continu reflect ev/sal
multipl median high growth low growth smid cap
med-tech turnaround unlik captur one year forward
multipl increasingli visibl market commerci improv
platform pipelin expans investor may will look farther
later year
price target reflect sale estim
median valuat low growth high growth smid
materi share gain expans market growth near term
acceler innov new indic progress faster
timelin expect combin better expect share gain
drive sale acceler high teen lead substanti
re-rat multipl
inflect headwind omnia launch late
launch lead materi acceler share gain grow
mid-teen expans initi drive market growth enthusiasm
near data readout
growth slow competit headwind less differenti omnia
launch fail catalyz sale less differenti combin upstart
competit execut issu lead growth mid singl digit lead
multipl contract
believ new platform launch
late catalyz acceler share
gain
competit risk clinic
product perspect well understood
clinic data expand key
data pain diabet neuropathi non-
surgic back come
pt ww share increas
revenu
pt us share increas
revenu
pt us market growth assum
pro rata share increas revenu
competit launch data on-going
risk achiev price
and/or omnia launch fail catalyz
upstart competitor could acquir
and/or obtain fund launch take
million except ep
accret redeem convert prefer stock redempt valu
dollar million except per share data
good sold
dollar million except per share data
dollar million except per share data
accumul comprehens loss
dollar million except per share data
non-cash loss extinguish debt
payment origin issu discount
provis doubt account
write-down inventori
unreal loss foreign currenc transact
purchas invest
proce matur invest
chang restrict cash
proce issuanc common stock underwritten public offering-
proce issuanc convert note
convert note initi issuanc discount debt issuanc cost
proce issuanc warrant
purchas convert note hedg
repay debt
purchas common stock proce issuanc common stock stock option exercis
begin period
end period
million
